Hitchhiking novel nanozymes on Bacillus licheniformis as an interactive reinforced bioactive platform for multifaceted therapy of ulcerative colitis.

The APPCs nanozymes were successfully synthesized with monodisperse ultrafine nanoceria of approximately 5 nm incorporated into a polyphenolic matrix capable of loading flavonoids.

• Nanoceria particles were described as 'monodisperse ultrafine nanoceria (5 nm)'
• The nanozymes contain 'high density of reactive oxygen species-reacting active sites, including monodisperse ultrafine nanoceria and polyphenolic groups'
• The platform enabled loading of additional agents such as flavonoids within the hybrid nanozyme structure
• The design was intended to 'imitate the intracellular antioxidant defense system'

BL@APPCs demonstrated enhanced accumulation and retention on inflamed colonic mucosa due to pH-sensitive and mucoadhesive single-cell nanocoating properties.

• The single-cell nanocoating was characterized as 'pH-sensitive and mucoadhesive'
• Enhanced accumulation and retention was specifically observed on 'inflamed colonic mucosa'
• The coating enabled 'controlled delivery and targeted uptake of the hitchhiked APPCs'
• The hierarchical targeting advantages were identified as a key feature of the platform's mechanism

APPCs protected both cells and probiotics from oxidative stress while mitigating inflammation through cascade enzymatic activities and flavonoid pharmacological activities.

• The nanozymes demonstrated 'cascade enzymatic activities' alongside pharmacological activities of flavonoids
• Protection was conferred to both host cells and the probiotic Bacillus licheniformis from oxidative stress
• The platform leveraged multiple simultaneous mechanisms: nano-catalytic therapy, bacteriotherapy, and flavonoid therapy
• The reactive oxygen species-reacting active sites were central to the antioxidant mechanism

BL@APPC treatment demonstrated significant therapeutic efficacy in both preventing and treating ulcerative colitis in murine models.

• Efficacy was demonstrated in murine models of UC in both prevention and treatment contexts
• The platform addressed 'oxidative stress, inflammatory cascades, gut microbiota dysbiosis, and compromised barrier function'
• Treatment was described as 'precise, multifaceted, and sustained'
• BL@APPCs were tested as a 'localized and comprehensive strategy for managing UC'

BL@APPC treatment effectively restored intestinal barrier functions in UC murine models.

• The paper states 'BL@APPC treatment effectively restored intestinal barrier functions'
• Compromised barrier function was identified as one of the key pathological features of UC targeted by this platform
• Restoration of barrier function was achieved alongside anti-inflammatory and antioxidant effects
• The hierarchical assembly structure was cited as contributing to these outcomes

BL@APPC treatment remodeled gut microbial homeostasis in UC murine models.

• The paper states the treatment 'remodeled gut microbial homeostasis'
• Gut microbiota dysbiosis was identified as one of the intricate pathological factors in UC that the platform was designed to address
• Bacillus licheniformis as a probiotic component contributed to the bacteriotherapy aspect of the multifaceted treatment
• Remodeling of gut microbiota was achieved in conjunction with restoration of intestinal barrier function

The BL@APPCs platform demonstrated favorable biosafety profiles.

• Biosafety was explicitly listed as one of the favorable characteristics: 'hierarchical assembly structure, diverse biological activities, hierarchical targeting advantages, and favorable biosafety'
• The platform was designed for localized delivery to the colon, which may contribute to its safety profile
• Bacillus licheniformis was used as the biological carrier component, representing an established probiotic organism
• The platform's safety was considered sufficient to support its characterization as suitable for managing UC

The BL@APPCs platform was designed with a hierarchical assembly structure enabling interactions among three distinct therapeutic modalities.

• The three modalities were described as 'advanced nano-catalytic therapy, bacteriotherapy, and flavonoid therapy'
• The platform is described as 'interactive reinforced,' suggesting synergistic interactions among the therapeutic components
• Each 'bioactive unit within this platform consists a single Bacillus licheniformis (BL) integrated with multiple hybrid nanozymes (APPCs)'
• The hierarchical structure provided 'hierarchical targeting advantages' for localized colonic delivery